Richard Partington r.partington@keele.ac.uk
Comorbidities in patients with polymyalgia rheumatica prior to and following diagnosis: A case control and cohort study
Partington, Richard; Muller, Sara; Mallen, Christian D; Abdul Sultan, Alyshah; Helliwell, Toby
Authors
Sara Muller s.muller@keele.ac.uk
Christian Mallen c.d.mallen@keele.ac.uk
Alyshah Abdul Sultan
Toby Helliwell t.helliwell@keele.ac.uk
Abstract
Objectives: To determine the burden of comorbidities, including glucocorticoid (GC) related adverse effects, in patients with polymyalgia rheumatica (PMR) before and after diagnosis.
Methods: We extracted anonymised electronic medical records of patients over the age of 40 years from the Clinical Practice Research Datalink from 1990-2016. Patients with PMR were individually matched on age, sex and registered General Practice to between three and five controls. The prevalence, cumulative probability and likelihood of a range of comorbidities was estimated. Odds ratios (ORs) and hazard ratios (HRs) were calculated using conditional logistic regression and Cox proportional hazards regression respectively, adjusted for a wide range of covariates.
Results: 31,984 patients with PMR were matched to 149,436 controls. PMR was prospectively associated with vascular disease (adjusted HR 1.23 [95% confidence interval (CI) 1.19, 1.28]), as well as respiratory (HR 1.25 [1.18, 1.32]), renal (HR 1.34 [1.30, 1.39]), and autoimmune diseases (HR 4.68 [4.35, 5.03]). Conversely, before PMR diagnosis, the risk of cancer (adjusted OR [OR] 0.89 [0.86, 0.93]) and neurological disease (OR 0.36 [0.33, 0.40]) was significantly lower. Patients with PMR had an increased risk of comorbidities associated with glucocorticoid (GC) use.
Conclusions
Patients with PMR have a high comorbidity burden, both before and after diagnosis. Whilst further work is needed to more fully understand these associations, clinicians should be aware of the high prevalence of comorbid conditions in this group and the impact that treatment with glucocorticoids may have on comorbidity.
Citation
Partington, R., Muller, S., Mallen, C. D., Abdul Sultan, A., & Helliwell, T. (2020). Comorbidities in patients with polymyalgia rheumatica prior to and following diagnosis: A case control and cohort study. Seminars in Arthritis and Rheumatism, 50(4), 663-672. https://doi.org/10.1016/j.semarthrit.2020.05.003
Journal Article Type | Article |
---|---|
Acceptance Date | May 15, 2020 |
Online Publication Date | May 26, 2020 |
Publication Date | 2020-08 |
Journal | Seminars in Arthritis and Rheumatism |
Print ISSN | 0049-0172 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 50 |
Issue | 4 |
Pages | 663-672 |
DOI | https://doi.org/10.1016/j.semarthrit.2020.05.003 |
Keywords | Polymyalgia rheumatica; Epidemiology; Comorbidity; Cohort; Case control |
Publisher URL | https://doi.org/10.1016/j.semarthrit.2020.05.003 |
PMID | 32512261 |
Files
Partington Complete Article.pdf
(1.4 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Comorbidities in polymyalgia rheumatica: a systematic review
(2018)
Journal Article
The real evidence for polymyalgia rheumatic as a paraneoplastic syndrome.
(2018)
Journal Article
The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome.
(2018)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search